Results 81 to 90 of about 164,625 (307)

Acute lymphoblastic leukaemia [PDF]

The Lancet, 2013
Acute lymphoblastic leukaemia occurs in both children and adults but its incidence peaks between 2 and 5 years of age. Causation is multifactorial and exogenous or endogenous exposures, genetic susceptibility, and chance have roles. Survival in paediatric acute lymphoblastic leukaemia has improved to roughly 90% in trials with risk stratification by ...
Inaba, H., Greaves, M., Mullighan, C.G.
openaire   +3 more sources

MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy [PDF]

, 2017
Methotrexate (MTX) is an important component in the therapy used to treat childhood acute lymphoblastic leukemia (ALL). Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme for MTX pharmacokinetics.
Gutiérrez Camino, Ángela, Muñoz Maldonado, Carmen, Umerez, Maitane, Umerez Igartua, Maitane, Martín Guerrero, Idoia, García-Orad Carles, África   +5 more
core   +1 more source

A Novel NR3C1 Frameshift Variant Associated With Familial Glucocorticoid Resistance Syndrome: An Integrated Analysis of Steroid Profiling and Structural Modeling

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Glucocorticoid resistance syndrome (GRS) is a rare hereditary disorder caused by pathogenic variants in NR3C1, characterized by marked phenotypic heterogeneity and frequent misdiagnosis as primary aldosteronism or subclinical Cushing's syndrome.
Sufang Yun, Zhifeng Zhu, Fengye Zhou, Ying Liu, Chunfang Liang, Haitao Ju, Lin Lu, Zhaoli Yan   +7 more
wiley   +1 more source

Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia

Haematologica, 2011
The runt-related transcription factor 1, RUNX1, is crucial in the development of myeloid and lymphoid cell lineages and has been reported to be mutated in myeloid malignancies in approximately 30% of cases.
Vera Grossmann, Wolfgang Kern, Stefan Harbich, Tamara Alpermann, Sabine Jeromin, Susanne Schnittger, Claudia Haferlach, Torsten Haferlach, Alexander Kohlmann   +8 more
doaj   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

British Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis, Leiah J. Brigitha, Lidwien M. Hanff, Alwin D. R. Huitema, Inge M. van der Sluis, Meta H. M. Diekstra   +5 more
wiley   +1 more source

A case report of secondary B-cell acute lymphoblastic leukemia treated with a combination of FLT3 inhibitor and decitabine

Frontiers in Oncology
Secondary acute lymphoblastic leukemia (s-ALL) refers to acute lymphoblastic leukemia that occurs after a previous malignant tumor, including therapy-related acute lymphoblastic leukemia (t-ALL) and prior malignant tumor acute lymphoblastic leukemia (pm ...
Mengci Hu, Wenzhe Li, Pan Li, Jie Tan, Ya Wang, Ya Wang   +5 more
doaj   +1 more source

TAL2 (T-cell acute lymphoblastic leukemia 2) [PDF]

, 2005
Review on TAL2 (T-cell acute lymphoblastic leukemia 2), with data on DNA, on the protein encoded, and where the gene is ...
Vanura, K
core   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Emerging Pharmacotherapies for Adult Patients with Acute Lymphoblastic Leukemia

, 2012
Acute lymphoblastic leukemia (ALL) treatment regimes are amongst the longest, most intensive and complex used in hemato-oncology. Despite this, while treatment of pediatric ALL is a success story, we are far from being able to ensure a durable response ...
Lydia Lee, Adele K. Fielding
core   +1 more source

Precision medicine in paediatrics: Progress and priorities

British Journal of Clinical Pharmacology, EarlyView.
Precision medicine is revolutionizing personalized healthcare, advancing both diagnostics and therapeutics at an unprecedented pace. Reviewing the paediatric applications of pharmacometrics, pharmacogenomics and advanced therapy medicinal products highlights not only the relevance of these exciting innovations to frontline care but also the significant
Nicola Husain, Claire Booth, Joseph F. Standing, Charlotte I. S. Barker   +3 more
wiley   +1 more source